NGLFINE
NGL Fine-Chem Limited
NSELast Traded Price
₹2810
-91.1 (-3.14%)
Open
₹2897.4
High
₹2897.4
Low
₹2800
Prev Close
₹2901.1
Industry
Pharmaceuticals
Market Cap
1736.02 Cr
Filing History
Recent corporate announcements and filings for NGLFINE
Governance
Positive
2026-08-25 21:52
- The 45th Annual General Meeting (AGM) of NGL Fine-Chem Limited was held on Tuesday, August 25, 2026, via Video Conferencing.
- Members adopted the audited financial statements for the financial year ended March 31, 2026.
- A Final Dividend for the financial year ended March 31, 2026, was declared.
- Re-appointments of Mr. Rajesh Lawande as Whole-Time Director and Mrs. Sarala Menon as Independent Director were approved.
- The Chairman discussed the company's FY 2025-26 performance, progress of greenfield expansion, Q1 FY 2026-27 performance, and long-term growth strategy.
Financials
Positive
2026-08-17 15:04
- Q1 FY27 Revenue from Operations ₹139.16Cr vs ₹104.19Cr (▲33.57% YoY)
- EBITDA ₹23.29Cr vs ₹10.97Cr (▲112.21% YoY)
- PAT ₹18.40Cr vs ₹9.24Cr (▲99.09% YoY)
- EBITDA Margin 16.73% vs 10.53% (▲620bps)
- Management noted healthy operating margins but expects moderation in coming quarters as price realisations normalise, viewing it as a natural correction.
- Phase II capex remains on schedule, expected to commission in the current quarter, with commercial production from H2FY27.
Governance
Negative
2026-08-12 19:55
CRITICAL RED FLAG DETECTED
- NGL Fine-Chem Limited received fines of ₹11,800 from both BSE and NSE for non-compliance/delay in intimating a Board Meeting under Regulation 29(2)/29(3) for May 2026. The Board noted the delay was inadvertent and stated that internal compliance mechanisms have been strengthened.
Financials
Positive
2026-08-12 19:10
- Q1 FY27 Consolidated Revenue ₹13,916.28L vs ₹10,418.54L (▲33.57% YoY)
- EBITDA ₹2,328.77L vs ₹1,097.40L (▲112.21% YoY)
- PAT ₹1,839.72L vs ₹924.06L (▲99.09% YoY)
- EBITDA Margin 16.73% vs 10.53% (▲620bps)
Financials
Positive
2026-08-12 18:58
- Q1 FY27 Consolidated Revenue ₹139.16Cr vs ₹104.19Cr (▲33.57% YoY)
- EBITDA ₹23.29Cr vs ₹10.97Cr (▲112.21% YoY)
- PAT ₹18.40Cr vs ₹9.24Cr (▲99.09% YoY)
- EBITDA Margin 16.73% vs 10.53% (▲620bps)